Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)We decrease our PT to $12 from $15, using a target EV/26E EBITDA multiple of ~10x, a discount to Core Tools peers, which we view as justified in light of slower sales growth and lower EBITDA margins. Key takes from the call: 1. Although Lab Solutions revenue was in line with expectations, the Company continues to face high levels of competitive intensity, driven by the challenging funding and policy-related environment. Mgmt noted that this headwind is most pronounced among large biopharma accounts. The Company is implementing several actions in Lab Solutions to protect and grow market share, including leveraging pricing as a tool. The recent strategic initiatives have negatively impacted segment margins in 2Q, and are expected to continue pressuring margins in the near future.